The identification of clinical and genetic parameters to predict the outcome in advanced colorectal cancer is a key issue in the management of this disease. We ascertained whether the clinical determinants of survival defined in a large cohort of patients treated with 5-fluorouracil (5-FU) (European Organization for the Research and Treatment of Cancer, EORTC model) also apply to 109 colorectal cancer patients receiving a therapy including oxaliplatin/5-FU as their first-line treatment. Our results confirm the considerable discriminatory power of the clinical model proposed in patients treated with a combined chemotherapy regimen. With the aim of identifying additional genetic prognostic parameters, we determined whether the polymorphisms in the promoter region of the thymidylate synthase (TS) gene that modifies the number of operative binding sites of a transcription factor (USF) could predict the clinical outcome of our patients and complement the EORTC clinical model. Our results indicate that this new genetic parameter (the number of USF-binding sites) could be considered when evaluating the role of TS genotype in the efficacy of the 5-FU-based regimens. Further, confirmatory studies aimed at evaluating the effect of the number of binding sites of transcription factors for selecting 5-FU-treated patients are warranted.
Introduction
A high proportion of colorectal cancer (CRC), which is a leading cause of cancerrelated morbidity and mortality in the Western world, is diagnosed at advanced stages when chemotherapy is required for its management. 5-Fluorouracil (5-FU) is a folate-pathway inhibitor that has been available for 50 years, and continues to be a mainstay of treatment of advanced disease. 1 Its combination with oxaliplatin has become standard for the first and second lines treatment of CRC. a stable complex with thymidylate synthase (TS), inhibiting the activity of the enzyme. 3, 4 Although over time different clinical parameters have been proposed as prognostic markers, there has not been a consensus on the relevance of these prognostic factors. This situation prompted Köhne et al. 5 to perform a multivariate analysis of the clinical data of 3825 metastatic CRC patients treated with 5-FU. These authors defined four baseline clinical parameters (performance status, white blood cell (WBC) count, alkaline phosphatase and number of metastatic sites), which allow the classification of the patients into three clearly separated risk groups. The authors suggested that any molecular or biological new marker should be validated against these clinical parameters.
Recently, different genetic markers (TS, dihydropyrimidine dehydrogenase and methylenetetrahydrofolate reductase gene polymorphisms) have been evaluated as predictors of outcome in CRC patients treated with fluoropyrimidines. TS is the marker that has been most often found to predict fluoropyrimidine responsiveness in these patients. [6] [7] [8] [9] [10] [11] [12] [13] [14] In the TS gene, three different polymorphisms have been described in its 5 0 -untranslated region (UTR) region. The first one consists in the variation in the number of a 28 bp tandemly repeated sequence. 15 Although alleles containing two, three, four, five and nine copies of the repeated sequence have been described, alleles with two (TS*2) and three (TS*3) repeats are the most common alleles. The number of tandem repeats affects TS activity levels: TS mRNA with a three-repeat sequence has greater translational efficiency than that with the two-repeat sequence. 16, 17 The second polymorphism, described by Mandola et al.
18
is a G4C single-nucleotide polymorphisms (SNP) at the 12th nucleotide of the second repeat in the TS*3 alleles. This polymorphic substitution changes a critical residue in the USF E-box consensus element, abolishes the USF-1 binding and alters transcriptional activity. Kawakami et al. 19 confirmed the presence of the G4C polymorphic change (SNP) and classified each polymorphic allele as *2G, *2C, *3G and *3C in accordance with the combination of the SNP and variable number of tandem repeat. Recently, the existence of a third polymorphism, an infrequent TS *2 allele type carrying a G4C base change in the 12th nucleotide of both 28 bp repeats, has been described. 20 Although the limited number of patients carrying this TS *2 C allele does not allow a conclusion to be drawn, the authors speculate that patients with this condition should be the most sensitive to the effects of fluoropyrimidines.
Furthermore, in the 3 0 untranslated region of the TS gene, a frequent polymorphism, consisting of a 6 bp deletion, was discovered through searching the public Expressed Sequence Tag database. 21 This polymorphism causes mRNA instability and is associated with decreased intratumoral TS mRNA levels. 22 The present work has two objectives: first, to ascertain whether the clinical model validated by Köhne et al. 5 in a cohort of patients treated with 5-FU can also be used to classify CRC patients receiving a combined therapy as a firstline treatment that includes oxaliplatin/5-FU (FOLFOX); second, to determine whether the polymorphisms in the promoter region of the TS gene that modifies the number of operative binding sites of a transcription factor (USF) could predict the clinical outcome of our patients and complement the European Organization for Research and Treatment of Cancer (EORTC) clinical model.
Results
Clinical/genetic determinants and response A total of 109 patients who fulfilled all inclusion criteria were studied. Clinical data are shown in Table 1 . Table 2 shows the relationships between response and clinical/ molecular determinants. There were no significant differences in the clinical response between the patients grouped in accordance with the clinical classification (P ¼ 0.3). Interestingly, when the patients were classified taking into account the number of USF-binding sites in the promoter region of the TS gene, the percentage of patients in clinical remission decreased as the number of binding sites increased. The 6 bp deletion polymorphism does not show any role in the probability of achieving a clinical response. Moreover, neither clinical nor genetic variables included in a logistic regression analysis to evaluate clinical response were significant. Alkaline phosphatase levels o300 U/l 92 (84%) X300 U/l 17 (16%)
Clinical/genetic determinants and survival Table 3 shows the univariate analysis of overall survival (OS) in relation to clinical and genetic determinants. There were significant differences in the survival between the patients grouped in accordance with the clinical classification (P ¼ 0.0002) (Figure 1a ). The TS genotype of the 5 0 region classifies the patients into three groups according to the number of USF active binding sites with a significantly different median OS (P ¼ 0.003) (Figure 1b ). No differences in survival can be related to the 6 bp deletion polymorphism (P ¼ 0.3). In the Cox regression model, which includes both the clinical and the genetic determinants, the clinical classification and the number of USF-binding sites retain their independent predictive value for survival (Table 4) .
Intermediate-risk patients were two times more at risk of dying than low-risk patients. Likewise, high-risk patients had a probability of death 3.6 times greater than low-risk patients. The group of patients with three binding sites were 1.8 times more at risk of dying than patients with two (Table 5 ). In patients with an intermediate clinical risk, this genetic parameter clearly discriminates three groups with a different survival (P ¼ 0.03), whereas no differences in survival were demonstrated in the remaining groups of patients.
Discussion

Clinical determinants
The identification of clinical parameters to predict the outcome in advanced CRC is a key issue in the management of this disease. A number of clinical factors such as performance status, lactate dehydrogenase values, WBC count, and so on have been identified as prognostic markers in different studies. However, no consensus on the importance of these prognostic factors has been attained. In an attempt to design a definitive prognostic clinical model for patients with metastatic CRC treated with 5-FU-based chemotherapy, Köhne CH et al. 5 carried out a multivariate analysis in a large number of cases (n ¼ 3825). These authors studied 23 variables, of which eight clinical parameters were significant. Nevertheless, to devise a more simplified model, patient risk groups with similar outcomes were combined and three clearly separated risk groups were defined with the use of only four clinical parameters (performance status, level of WBC count, alkaline phosphatase and number of involved tumor sites). But, as pointed out by the authors, whether the model could also apply to patients receiving 5-FU in combination with CPT-11 or oxaliplatin as their first-line treatment is unknown. We, accordingly, applied this model to a cohort of 109 CRC patients receiving a uniform combination therapy including oxaliplatin/5-FU as their first-line treatment. Our results demonstrate that three risk groups can also be clearly defined with significantly different median survivals (11 months in the highrisk group, 19 in the intermediate and 41 in the low-risk group), confirming the considerable discriminating power of the clinical model proposed.
Genetic determinants
A number of clinical studies indicate that the TS expression could predict overall outcome and response to 5-FU in CRC patients. Recent studies have confirmed the role of the TS genotype as a useful parameter to predict response and survival in CRC patients treated with 5-FU alone or in combination with CPT11 or oxaliplatin. [6] [7] [8] [23] [24] [25] The TS genotype has been demonstrated to be an independent predictor of progression-free and OS in the Cox regression models after adjustment to the other clinical variables. 9 An important mechanism of expression control of the TS gene could be attributed to polymorphisms in the promoter region of this gene. Two G4C substitutions in the 12th nucleotide of the polymorphic repeats located in this 5 0 -UTR region change a critical residue in the USF E-box consensus elements, abolish the USF binding and alter transcriptional activity. We hypothesize that as the number of binding sites increases, the resistance to 5-FU will be greater, resulting in a poorer outcome. For this reason, in the present work the 109 patients were classified into different groups in accordance with the number of operative USF-binding sites.
As regards the clinical response, although a statistically significant relationship was not achieved, the percentage of patients in clinical remission decreased as the number of binding sites increased. When considering the OS, major differences were observed: a poor survival in patients with four binding sites, an intermediate survival in patients with three binding sites and the best OS in the group of patients with only two binding sites (P ¼ 0.003). The results of the Cox regression analysis demonstrate that the number of USF-binding sites retains its independent predictive value and complements the predictive value of outcome of the EORTC clinical model in patients with metastatic colorectal cancer treated with 5-FU and oxaliplatin.
When the OS was calculated taking into account the number of binding sites for each group of patients, classified according to the clinical model, we observed that this genetic marker clearly discriminated three different survival groups in intermediate-risk patients.
In conclusion, our findings demonstrate the predictive value of the clinical model defined by Köhne et al. when applied to patients treated with a combined chemotherapy regimen. Furthermore, these results indicate that the number of USF-binding sites in the promoter region of the TS gene can be considered when evaluating the role of TS genotype on 5-FU efficacy. Further confirmatory studies aimed at evaluating the effect of the number of binding sites of transcription factors for selecting 5-FU-treated patients are warranted.
Materials and methods
Patients
A total of 109 patients diagnosed with metastatic CRC and undergoing 5-FU and oxaliplatin as a first-line 
Clinical parameters
Relevant clinical data were obtained from clinical records (gender, age, ECOG, adjuvant therapy, number of chemotherapy cycles, number of metastatic sites, colon vs rectum involvement, WBC count, alkaline phosphatase). Response to treatment and OS were also analyzed. Clinical response was assessed by CT scan every 3 months after the start of chemotherapy and was defined according to the World Health Organization criteria. 26 OS was calculated from the start of chemotherapy to death regardless of the cause.
TS genotyping assays
Genomic DNA was extracted from peripheral leukocytes by the salting-out procedure. 27 For the analysis of the 28-repeat polymorphism, a fragment containing the repeats was amplified using the primers and the PCR conditions previously described. 15 DNA fragments of 242 bp (*3/*3), 214 bp (*2/*2) or both (*2/*3) were observed. Half of the PCR products of all cases genotype were digested with HaeIII 17, 18 followed by electrophoresis in 3.5% agarose gel containing ethidium bromide. The G to C change in the second repeat of the *3 alleles removes a HaeIII site, enabling the identification of the different alleles: *2 (66, 47, 45, 44 and 12 bp), *3C (94, 47, 45, 44 and 12 bp) and *3G (66, 47, 45, 44, 28 and 12 bp). TS*2 alleles carrying the novel polymorphism (G to C change in the first repeat) were identified by the presence of a 113 bp band after the HaeIII digestion. 20 As these G to C substitutions change a critical residue in the USF E-box consensus element, abolish USF-1 binding and alter transcriptional activity, TS genotypes of the patients were classified according the number of functionally binding sites (those with a G residue in the 12th position of the repeat).
TS 6 bp deletion polymorphism at nucleotide 1494 (TTAAAG) was amplified using the primers and the PCR previously described. 28 The À6 bp allele (152 bp) and the þ 6 bp allele (158 bp) were identified after 8% polyacrylamide gel electrophoresis and ethidium bromide staining.
Statistical analysis
Differences between categorical variables were measured by the w 2 -test. Logistic regression was used as a multivariate method to ascertain which variables independently predicted clinical response. Kaplan-Meier estimates and the log-rank test were methods used in univariate analysis of survival. A Cox regression model was used for OS multivariate analysis. The results were considered as statistically significant when bilateral P-values were less than 0.05.
